Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of AstraZeneca's CMG-901?
CMG-901 is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal...
Risk adjusted net present value: What is the current valuation of KeyMed Biosciences's CMG-901?
CMG-901 is a monoclonal antibody conjugated commercialized by KeyMed Biosciences, with a leading Phase III program in Adenocarcinoma Of The...
Risk adjusted net present value: What is the current valuation of AstraZeneca's CMG-901?
CMG-901 is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal...